Skip to main content
Figure 1 | BMC Psychiatry

Figure 1

From: Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder

Figure 1

Weight change (kg) and BMI change (kg/m 2 ) from baseline to 30-week endpoint in Studies 1 and 2. For Study 1 (N = 669), the mean (standard deviation [SD]) weight change was 5.4 kg (6.9); for Study 2 (N = 102), it was 5.2 kg (6.6). Data were grouped into intervals of 4 kg with midpoints of each interval shown along horizontal axes. The height of each bar corresponds to the proportion of patients whose weight change falls within that range. For Study 1 (N = 661), the mean (SD) BMI change was 1.9 (2/4) kg/m2; for Study 2, (N = 101), the mean (SD) BMI change was 1.8 (2.3) kg/m2. Data were grouped in intervals of 1 kg/m2 with midpoints of each interval shown along the horizontal axes. The height of each bar corresponds to the proportion of patients whose BMI change falls within that range.

Back to article page